Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Characterization of ASP8374, a fully-human, antagonistic anti-TIGIT monoclonal antibody.
Shirasuna K, Koelsch G, Seidel-Dugan C, Salmeron A, Steiner P, Winston WM, Brodkin HR, Nirschl CJ, Abbott S, Kinugasa F, Sugahara S, Ohori M, Takeuchi M, Hicklin DJ, Yoshida T. Shirasuna K, et al. Among authors: kinugasa f. Cancer Treat Res Commun. 2021;28:100433. doi: 10.1016/j.ctarc.2021.100433. Epub 2021 Jul 11. Cancer Treat Res Commun. 2021. PMID: 34273876 Free article.
Discovery of a novel Igβ and FcγRIIB cross-linking antibody, ASP2713, and its potential application in the treatment of systemic lupus erythematosus.
Kitanaga Y, Yamajuku D, Kubo S, Nakamura K, Maeda M, Seki M, Kaneko Y, Kinugasa F, Morokata T, Kondo Y, Yoshinari H, Nakayamada S, Sumida T, Tanaka Y. Kitanaga Y, et al. Among authors: kinugasa f. Int Immunopharmacol. 2021 Dec;101(Pt B):108343. doi: 10.1016/j.intimp.2021.108343. Epub 2021 Nov 12. Int Immunopharmacol. 2021. PMID: 34781122
Preclinical Characterization of ASP2713, a Novel Igβ and FcγRIIB Cross-Linking Antibody, for Prediction of Human Pharmacokinetics and Clinically Effective Dose.
Konishi K, Nakamura K, Hanada Y, Kitanaga Y, Kubo S, Kinugasa F, Yamajuku D, Maeda M, Yamamoto N, Minematsu T, Ohbuchi M, Kondo Y, Sumida T. Konishi K, et al. Among authors: kinugasa f. J Pharm Sci. 2022 Sep;111(9):2630-2638. doi: 10.1016/j.xphs.2022.06.006. Epub 2022 Jun 11. J Pharm Sci. 2022. PMID: 35700799
Effect of anti-claudin 18.2 monoclonal antibody zolbetuximab alone or combined with chemotherapy or programmed cell death-1 blockade in syngeneic and xenograft gastric cancer models.
Nishibata T, Weng J, Omori K, Sato Y, Nakazawa T, Suzuki T, Yamada T, Nakajo I, Kinugasa F, Türeci Ö, Şahin U, Yoshida T. Nishibata T, et al. Among authors: kinugasa f. J Pharmacol Sci. 2024 Jul;155(3):84-93. doi: 10.1016/j.jphs.2024.04.004. Epub 2024 Apr 18. J Pharmacol Sci. 2024. PMID: 38797537 Free article.
18 results